Mylan CEO claims to be frustrated in wake of EpiPen price controversy
EpiPens have been in the news lately—and not for the right reasons. The 400 percent increase in price over the last decade for the medication for allergic reactions has drawn criticism from the highest places. An article in Forbes takes Mylan, the company that produces the EpiPen, to task, directing specific questions to CEO Heather Bresch for her reaction to the controversy.
"When it comes to people and healthcare, pharmaceutical companies should take note of these recent debacles," writes Emily WIllingham in Forbes. "Perhaps it’s time to realize that for them, it’s not just about doing good business. Because their business is human health, it’s also about being a good business."
Check out the full article by clicking the link below:
Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.